Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen and aromatase inhibitors

Keyphrases

• In Cancer 100%
• Cancer Prevention 100%
• Pharmacogenetics 100%
• Cancer Treatment 100%
• Aromatase Inhibitors 100%
• Postmenopausal Women 66%
• Selective Estrogen Receptor Modulators 33%
• Estrogen 33%
• UDP-glucuronosyltransferase 33%
• Deactivation 33%
• Letrozole 33%
• Adverse Events 33%
• Adjuvant Therapy 33%
• Breast Cancer 33%
• Tamoxifen Therapy 33%
• Inter-individual Variability 33%
• Breast Cancer Patients 33%
• Resistance Development 33%
• Recurrent Disease 33%
• Third Generation 33%
• Clinical Follow-up 33%
• Metastatic Breast Cancer 33%
• Estrone 33%
• Deep Vein Thrombosis 33%
• Hot Flashes 33%
• Aromatase Activity 33%
• Metabolic Enzymes 33%
• Patient Response 33%
• Early Breast Cancer 33%
• Breast Cancer Mortality 33%
• Endometrial Cancer 33%

Medicine and Dentistry

• Aromatase Inhibitor 100%
• Cancer Prevention 100%
• Cancer Therapy 100%
• Tamoxifen 100%
• Pharmacogenetics 100%
• Breast Cancer 55%
• Postmenopause 22%
• Adjuvant Therapy 11%
• Letrozole 11%
• Adverse Event 11%
• Cancer Mortality 11%
• Recurrent Disease 11%
• Estrone 11%
• Hot Flush 11%
• Aromatase 11%
• Metastatic Breast Cancer 11%
• Deep Vein Thrombosis 11%
• Contralateral 11%
• Endometrial Cancer 11%
• Glucuronosyltransferase 11%
• Selective Estrogen Receptor Modulator 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Tamoxifen 100%
• Aromatase Inhibitor 100%
• Pharmacogenetics 100%
• Breast Cancer 55%
• Glucuronosyltransferase 11%
• Adverse Event 11%
• Cancer Mortality 11%
• Recurrent Disease 11%
• Metastatic Breast Cancer 11%
• Aromatase 11%
• Deep Vein Thrombosis 11%
• Estrone 11%
• Hot Flush 11%
• Endometrium Cancer 11%
• Selective Estrogen Receptor Modulator 11%